[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Guillot-Sestier et al., 2009 - Google Patents

The α-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo

Guillot-Sestier et al., 2009

View HTML @Full View
Document ID
15769121891685670525
Author
Guillot-Sestier M
Sunyach C
Druon C
Scarzello S
Checler F
Publication year
Publication venue
Journal of Biological Chemistry

External Links

Snippet

Cellular prion protein (PrP c) undergoes a disintegrin-mediated physiological cleavage, generating a soluble amino-terminal fragment (N1), the function of which remained unknown. Recombinant N1 inhibits staurosporine-induced caspase-3 activation by …
Continue reading at www.jbc.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Guillot-Sestier et al. The α-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo
Romero et al. The angiotensin‐(1‐7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation
Bloemberg et al. Autophagy, apoptosis, and mitochondria: molecular integration and physiological relevance in skeletal muscle
Camara et al. Mitochondrial VDAC1: a key gatekeeper as potential therapeutic target
Smilansky et al. The voltage-dependent anion channel 1 mediates amyloid β toxicity and represents a potential target for Alzheimer disease therapy
Tanik et al. Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy*♦
Yoo et al. FKBP8 LIRL‐dependent mitochondrial fragmentation facilitates mitophagy under stress conditions
Knafo et al. PTEN recruitment controls synaptic and cognitive function in Alzheimer's models
Sze et al. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro: a potential role in Alzheimer's disease
Arzoine et al. Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity
Meyer et al. Ischemic stroke injury is mediated by aberrant Cdk5
Gupta et al. PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance
Brittain et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2)
Xiang et al. Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer’s disease pathologies
Hashimoto et al. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3β pathway: Implications for neuroprotection
Huang et al. Paraquat induces cell death through impairing mitochondrial membrane permeability
Baik et al. P in1 promotes neuronal death in stroke by stabilizing N otch intracellular domain
Li et al. HIV‐1 inhibits long‐term potentiation and attenuates spatial learning
Anderson et al. Prohibitin is a positive modulator of mitochondrial function in PC 12 cells under oxidative stress
Nakano et al. Neuroprotective effects of VCP modulators in mouse models of glaucoma
US9730935B2 (en) Targeting a non-canonical notch signaling pathway for cancer treatment
Pathak et al. Retrograde degenerative signaling mediated by the p75 neurotrophin receptor requires p150Glued deacetylation by axonal HDAC1
Xiao et al. Switching of N-methyl-D-aspartate (NMDA) receptor-favorite intracellular signal pathways from ERK1/2 protein to p38 mitogen-activated protein kinase leads to developmental changes in NMDA neurotoxicity
Lim et al. Cytosolic PTEN-induced putative kinase 1 is stabilized by the NF-κB pathway and promotes non-selective mitophagy
Aicart-Ramos et al. A novel conserved domain mediates dimerization of protein kinase D (PKD) isoforms: dimerization is essential for PKD-dependent regulation of secretion and innate immunity